{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:25:57Z","timestamp":1791656757286,"version":"4.3.4"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["IZJFZ3_185646"],"award-info":[{"award-number":["IZJFZ3_185646"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_175585\/1"],"award-info":[{"award-number":["320030_175585\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.pt.2023.01.009","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T16:03:43Z","timestamp":1676649823000},"page":"272-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Ivermectin and moxidectin against soil-transmitted helminth infections"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-8198","authenticated-orcid":false,"given":"Eveline","family":"H\u00fcrlimann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-0744","authenticated-orcid":false,"given":"Daniela","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-3521","authenticated-orcid":false,"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2023.01.009_bb0005","series-title":"Saunders Handbook of Veterinary Drugs","first-page":"545","article-title":"Moxidectin","author":"Papich","year":"2016"},{"key":"10.1016\/j.pt.2023.01.009_bb0010","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nrmicro1048","article-title":"The life and times of ivermectin \u2013 a success story","volume":"2","author":"Omura","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2023.01.009_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2183\/pjab.87.13","article-title":"Ivermectin, 'wonder drug' from Japan: the human use perspective","volume":"87","author":"Crump","year":"2011","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.pt.2023.01.009_bb0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2007.08.023","article-title":"Ivermectin: 25 years and still going strong","volume":"31","author":"Omura","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.pt.2023.01.009_bb0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpddr.2019.06.002","article-title":"Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance","volume":"10","author":"Prichard","year":"2019","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2023.01.009_bb0030","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"Opoku","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2023.01.009_bb0035","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1473-3099(18)30233-0","article-title":"Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial","volume":"18","author":"Barda","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0040","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/cid\/cix278","article-title":"Efficacy of moxidectin versus ivermectin against Strongyloides stercoralis infections: a randomized, controlled noninferiority trial","volume":"65","author":"Barda","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0045","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/cid\/ciz326","article-title":"Efficacy and safety of ascending dosages of moxidectin and moxidectin-albendazole against Trichuris trichiura in adolescents: a randomized controlled trial","volume":"70","author":"Keller","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.apar.2018.08.002","article-title":"Drug combinations against soil-transmitted helminth infections","volume":"103","author":"Moser","year":"2019","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.pt.2023.01.009_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002165","article-title":"A public health response against Strongyloides stercoralis: time to look at soil-transmitted helminthiasis in full","volume":"7","author":"Krolewiecki","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0060","article-title":"Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis","volume":"358","author":"Moser","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.pt.2023.01.009_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008505","article-title":"The global progress of soil-transmitted helminthiases control in 2020 and World Health Organization targets for 2030","volume":"14","author":"Montresor","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006606","article-title":"Toward the 2020 goal of soil-transmitted helminthiasis control and elimination","volume":"12","author":"Becker","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpddr.2014.07.002","article-title":"Repurposing drugs for the treatment and control of helminth infections","volume":"4","author":"Panic","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2023.01.009_bb0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijpddr.2012.04.001","article-title":"Moxidectin and the avermectins: consanguinity but not identity","volume":"2","author":"Prichard","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2023.01.009_bb0085","article-title":"The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children)","author":"WHO","year":"2017"},{"key":"10.1016\/j.pt.2023.01.009_bb0090","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/BF01971780","article-title":"Avermectins - novel insecticides, acaricides and nematicides from a soil microorganism","volume":"37","author":"Putter","year":"1981","journal-title":"Experientia"},{"key":"10.1016\/j.pt.2023.01.009_bb0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1254\/fpj.122.527","article-title":"Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy","volume":"122","author":"Ikeda","year":"2003","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.pt.2023.01.009_bb0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pt.2020.10.005","article-title":"Ivermectin: an anthelmintic, an insecticide, and much more","volume":"37","author":"Martin","year":"2021","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2023.01.009_bb0105","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","article-title":"Moxidectin: an oral treatment for human onchocerciasis","volume":"18","author":"Milton","year":"2020","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.pt.2023.01.009_bb0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/vr.130.12.241","article-title":"Efficacy of moxidectin, nemadectin and ivermectin against an ivermectin-resistant strain of Haemonchus contortus in sheep","volume":"130","author":"Pankavich","year":"1992","journal-title":"Vet. Rec."},{"key":"10.1016\/j.pt.2023.01.009_bb0115","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.2147\/IDR.S332378","article-title":"Anthelmintic resistance and its mechanism: a review","volume":"14","author":"Fissiha","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.pt.2023.01.009_bb0120","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/0091270003257456","article-title":"The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans","volume":"43","author":"Cotreau","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2023.01.009_bb0125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2885.2012.01424.x","article-title":"Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin","volume":"36","author":"Janko","year":"2013","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2023.01.009_bb0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41572-020-0171-3","article-title":"Whipworm and roundworm infections","volume":"6","author":"Else","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.pt.2023.01.009_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1473-3099(21)00421-7","article-title":"Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in C\u00f4te d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blind, parallel-group, phase 3, randomised controlled trial","volume":"22","author":"H\u00fcrlimann","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0140","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1086\/657310","article-title":"Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial","volume":"51","author":"Knopp","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.12688\/gatesopenres.13615.1","article-title":"An adaptive phase II\/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol","volume":"6","author":"Krolewiecki","year":"2022","journal-title":"Gates Open Res."},{"key":"10.1016\/j.pt.2023.01.009_bb0150","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/cid\/ciab365","article-title":"Efficacy and safety of albendazole and high-dose ivermectin coadministration in school-aged children infected with Trichuris trichiura in Honduras: a randomized controlled trial","volume":"73","author":"Matamoros","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1473-3099(14)71050-3","volume":"15","author":"Speich","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0160","article-title":"Efficacy and safety of moxidectin and albendazole compared with ivermectin and albendazole coadministration in adolescents infected with Trichuris trichiura in Tanzania: an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","author":"Welsche","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0165","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/cid\/ciy246","article-title":"Efficacy and safety of ivermectin against Trichuris trichiura in preschool-aged and school-aged children: a randomized controlled dose-finding trial","volume":"67","author":"Wimmersberger","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0170","doi-asserted-by":"crossref","unstructured":"Sprecher, V.P. et al., Efficacy and safety of moxidectin-albendazole and ivermectin-albendazole combination therapy compared to albendazole monotherapy in adolescents and adults infected with Trichuris trichiura: a randomised controlled superiority trial, Available at SSRN: https:\/\/ssrn.com\/abstract=4345814 or http:\/\/dx.doi.org\/10.2139\/ssrn.4345814.","DOI":"10.2139\/ssrn.4345814"},{"key":"10.1016\/j.pt.2023.01.009_bb0175","series-title":"Assessing the Efficacy of Anthelminthic Drugs Against Schistosomiasis and Soil-transmitted Helminthiases","author":"WHO","year":"2013"},{"key":"10.1016\/j.pt.2023.01.009_bb0180","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41467-022-28658-1","article-title":"Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases","volume":"13","author":"Schneeberger","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2023.01.009_bb0185","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1473-3099(17)30487-5","volume":"17","author":"Moser","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0190","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1473-3099(20)30691-5","article-title":"Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial","volume":"21","author":"Hofmann","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009561","article-title":"Long-term outcomes of ivermectin-albendazole versus albendazole alone against soil-transmitted helminths: results from randomized controlled trials in Lao PDR and Pemba Island, Tanzania","volume":"15","author":"Keller","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13071-016-1406-8","article-title":"Efficacy and reinfection with soil-transmitted helminths 18-weeks post-treatment with albendazole-ivermectin, albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole","volume":"9","author":"Speich","year":"2016","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2023.01.009_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2022.106437","article-title":"Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia","volume":"231","author":"Eneanya","year":"2022","journal-title":"Acta Trop."},{"key":"10.1016\/j.pt.2023.01.009_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008642","article-title":"Impact of annual and semi-annual mass drug administration for lymphatic filariasis and onchocerciasis on hookworm infection in C\u00f4te d'Ivoire","volume":"14","author":"Loukouri","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0215","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/cts.13189","article-title":"Optimizing moxidectin dosing for Strongyloides stercoralis infections: insights from pharmacometric modeling","volume":"15","author":"Hofmann","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.pt.2023.01.009_bb0220","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.trstmh.2008.01.020","article-title":"Strongyloides hyperinfection syndrome: an emerging global infectious disease","volume":"102","author":"Marcos","year":"2008","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2023.01.009_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001044","article-title":"Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis","volume":"5","author":"Suputtamongkol","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0230","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s101560200013","article-title":"Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart","volume":"8","author":"Zaha","year":"2002","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.pt.2023.01.009_bb0235","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1473-3099(19)30289-0","article-title":"Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial","volume":"19","author":"Buonfrate","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0240","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S2214-109X(19)30453-X","article-title":"Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis","volume":"8","author":"Nicolas","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pt.2023.01.009_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpara.2009.11.001","article-title":"Unresolved issues in anthelmintic pharmacology for helminthiases of humans","volume":"40","author":"Geary","year":"2010","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.pt.2023.01.009_bb0250","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1039\/C8AY00828K","article-title":"Development and validation of a LC-MS\/MS method for ivermectin quantification in dried blood spots: application to a pharmacokinetic study in Trichuris trichiura-infected adults","volume":"10","author":"Schulz","year":"2018","journal-title":"Anal. Methods"},{"key":"10.1016\/j.pt.2023.01.009_bb0255","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jpba.2019.04.007","article-title":"Development and validation of an LC-MS\/MS method for the analysis of ivermectin in plasma, whole blood, and dried blood spots using a fully automatic extraction system","volume":"172","author":"Duthaler","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.pt.2023.01.009_bb0260","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/BF00637608","article-title":"The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution","volume":"35","author":"Edwards","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2023.01.009_bb0265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00195923","article-title":"Ivermectin levels in human breast milk","volume":"46","author":"Ogbuokiri","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2023.01.009_bb0270","first-page":"P94","article-title":"Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers","volume":"73","author":"Vanapalli","year":"2003","journal-title":"Clin. Pharmacol. The."},{"key":"10.1016\/j.pt.2023.01.009_bb0275","first-page":"203","article-title":"Human pharmacokinetics of orally taken ivermectin","volume":"17","author":"Long","year":"2001","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2023.01.009_bb0280","series-title":"Ivermectin and Abamectin","first-page":"113","article-title":"Pharmacokinetics of ivermectin in animals and humans","author":"Fink","year":"1989"},{"key":"10.1016\/j.pt.2023.01.009_bb0285","first-page":"79","article-title":"Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus","volume":"42","author":"Elkassaby","year":"1991","journal-title":"Trop. Med. Parasitol."},{"key":"10.1016\/j.pt.2023.01.009_bb0290","first-page":"426","article-title":"Protein-binding and ivermectin estimations in patients with onchocerciasis","volume":"53","author":"Okonkwo","year":"1993","journal-title":"Clin. Pharmacol. The."},{"key":"10.1016\/j.pt.2023.01.009_bb0295","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4269\/ajtmh.1995.52.94","article-title":"Ivermectin detection in serum of onchocerciasis patients \u2013 relationship to adverse reactions","volume":"52","author":"Njoo","year":"1995","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2023.01.009_bb0300","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002237994","article-title":"Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects","volume":"42","author":"Guzzo","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2023.01.009_bb0305","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1179\/000349803235001697","article-title":"The co-administration of ivermectin and albendazole \u2013 safety, pharmacokinetics and efficacy against Onchocerca volvulus","volume":"97","author":"Awadzi","year":"2003","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.pt.2023.01.009_bb0310","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpt.1219","article-title":"Pharmacokinetics-pharmacodynamics of high-dose ivermectin with dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL)","volume":"105","author":"Smit","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2023.01.009_bb0315","first-page":"609","article-title":"Determination of ivermectin in human plasma by high-performance liquid chromatography","volume":"43","author":"Krishna","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pt.2023.01.009_bb0320","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bcp.13840","article-title":"Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers","volume":"85","author":"Duthaler","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2023.01.009_bb0325","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jac\/dkz083","article-title":"Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2\u201312 years","volume":"74","author":"Schulz","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2023.01.009_bb0330","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/1346-8138.13321","article-title":"Effect of high-fat meal intake on the pharmacokinetic profile of ivermectin in Japanese patients with scabies","volume":"43","author":"Miyajima","year":"2016","journal-title":"J. Dermatol."},{"key":"10.1016\/j.pt.2023.01.009_bb0335","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cpt.1456","article-title":"Ivermectin dosing strategy to achieve equivalent exposure coverage in children and adults","volume":"106","author":"Brussee","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2023.01.009_bb0340","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.trstmh.2005.05.017","article-title":"Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations","volume":"100","author":"Na-Bangchang","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2023.01.009_bb0345","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis","volume":"62","author":"Thomsen","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.914886","article-title":"Pharmacokinetic characterization and comparative bioavailability of an innovative orodispersible fixed-dose combination of ivermectin and albendazole: a single dose, open label, sequence randomized, crossover clinical trial in healthy volunteers","volume":"13","author":"Algorta","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pt.2023.01.009_bb0355","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cts.12583","article-title":"Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study","volume":"11","author":"Kinrade","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.pt.2023.01.009_bb0360","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4269\/ajtmh.2012.11-0415","article-title":"The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial","volume":"86","author":"Korth-Bradley","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2023.01.009_bb0365","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cpdd.81","article-title":"Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects","volume":"3","author":"Korth-Bradley","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.pt.2023.01.009_bb0370","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/2160763X11432508","article-title":"Relative bioavailability of liquid and tablet formulations of the antiparasitic moxidectin","volume":"1","author":"Korth-Bradley","year":"2012","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.pt.2023.01.009_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4389","article-title":"Bioanalytical method development and validation of moxidectin in plasma by LC-MS\/MS: Application to in vitro metabolism","volume":"33","author":"Chhonker","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.pt.2023.01.009_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122556","volume":"1166","author":"Hofmann","year":"2021","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.pt.2023.01.009_bb0385","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1128\/AAC.00311-11","article-title":"Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women","volume":"55","author":"Korth-Bradley","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2023.01.009_bb0390","first-page":"238","article-title":"Determining the optimal dose of moxidectin for onchocerciasis via pharmacokinetic-pharmacodynamic (pk-pd) modelling of data from healthy volunteers and patients with onchocerciasis","volume":"97","author":"Jamsen","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2023.01.009_bb0395","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-021-01048-4","article-title":"Characterization of the population pharmacokinetics of moxidectin in adults infected with Strongyloides stercoralis: support for a fixed-dose treatment regimen","volume":"61","author":"Smit","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pt.2023.01.009_bb0400","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12936-017-1825-9","article-title":"Ivermectin and malaria control","volume":"16","author":"Omura","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2023.01.009_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005030","article-title":"Preclinical study of single-dose moxidectin, a new oral treatment for scabies: efficacy, safety, and pharmacokinetics compared to two-dose ivermectin in a porcine model","volume":"10","author":"Bernigaud","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0410","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/trstmh\/trab114","article-title":"Broadening the range of use cases for ivermectin \u2013 a review of the evidence","volume":"116","author":"Kositz","year":"2022","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2023.01.009_bb0415","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/inthealth\/ihx054","article-title":"Alternative treatment strategies to accelerate the elimination of onchocerciasis","volume":"10","author":"Boussinesq","year":"2018","journal-title":"Int. Health"},{"key":"10.1016\/j.pt.2023.01.009_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004389","article-title":"Prospects for moxidectin as a new oral treatment for human scabies","volume":"10","author":"Mounsey","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.009_bb0425","series-title":"Ending the Neglect to Attain the Sustainable Development Goals \u2013 a Road Map for Neglected Tropical Diseases 2021\u20132030","author":"WHO","year":"2020"},{"key":"10.1016\/j.pt.2023.01.009_bb0430","series-title":"Optimizing Treatment for Children in the Developing World","first-page":"33","article-title":"Challenges in pediatric oral dosing","author":"Goldman","year":"2015"},{"key":"10.1016\/j.pt.2023.01.009_bb0435","series-title":"Deworming Adolescent Girls and Women of Reproductive Age: Policy Brief","author":"WHO","year":"2021"},{"key":"10.1016\/j.pt.2023.01.009_bb0440","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/pathogens10121588","article-title":"Treatment of pregnant women with ivermectin during mass drug distribution: time to investigate its safety and potential benefits","volume":"10","author":"Erber","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.pt.2023.01.009_bb0445","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(18)32591-1","article-title":"Effects, equity, and cost of school-based and community-wide treatment strategies for soil-transmitted helminths in Kenya: a cluster-randomised controlled trial","volume":"393","author":"Pullan","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2023.01.009_bb0450","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/cid\/ciz742","article-title":"The elimination of neglected tropical diseases: a case study exemplifying how foreign assistance funding can be catalytic in reducing the burden of major global health conditions","volume":"70","author":"Wainwright","year":"2020","journal-title":"Clin. Infect. Dis."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492223000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492223000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:53:29Z","timestamp":1778615609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492223000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1471492223000132"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2023.01.009","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivermectin and moxidectin against soil-transmitted helminth infections","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2023.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}